NCT01121770View on ClinicalTrials.gov

"Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction"

PHASE1CompletedINTERVENTIONAL

Enrollment

9

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

October 31, 2012

Study Completion Date

February 28, 2013

Conditions

Renal Insufficiency

Interventions

DRUG

fondaparinux sodium injection

1.5mg subcutaneously every day

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

Duke University

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

Duke University

OTHER

NCT01121770 - "Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction" | Biotech Hunter | Biotech Hunter